This handout is for abdominal aortic aneurysm (surveillance + rupture). Your care team identified this based on: pulsatile abdominal mass on exam (svs 2024).
Other reasons your team may use this plan: abdominal/back pain + hypotension/syncope — rupture suspicion (esvs 2019; svs 2024); us/ct showing infrarenal aorta >=3.0 cm (svs 2024; esvs 2019); nhs / uspstf aaa screening — men 65-75 / select women (uspstf 2019; esvs 2019).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| atorvastatin | 40-80 mg | PO | once daily | ESVS 2019; SVS 2024 — statin reduces CV mortality in AAA; pleiotropic effect on aneurysm growth uncertain |
| aspirin | 81 mg | PO | once daily | CV mortality benefit; not aneurysm-specific (SVS 2024; ESC 2024) |
| lisinopril | 10-40 mg | PO | once daily | BP control to <130/80 (SVS 2024); ACEi acceptable, no aneurysm-growth-specific evidence |
| losartan | 50-100 mg | PO | once daily | Marfan benefit — COMPARE trial (Radonic EJCTS 2012); reasonable in CTD AAA (ESC 2024) |
Plan: AAA — surveillance + medical optimization + repair (ESVS 2024 / NICE NG156 / SVS 2018)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Long-term smoking cessation; BP and statin optimization; family screening recommendations (SVS 2024; ESC 2024)
Guideline: ESVS 2024 (Wanhainen et al, Eur J Vasc Endovasc Surg 2024) + NICE NG156 + SVS 2018 + 2022 ACC/AHA Aortic + 2024 ESC PAD/Aortic